Piperazine (piperazine hexahydrate has the empirical formula, C4H,ON26H20) is used medicinally in the form of the hydrate, the citrate, the tartrate, the phosphate, and the adipate and in various other more complex compounds. It was first used about the turn of the century for the treatment of gout but its relative ineffectiveness led it into desuetude (Brown, Chan, and Hussey, I956) . It has lately been extensively used as a human and animal anthelminthic, and certain of its compounds have been investigated for the treatment of cancer (McNair, Wibin, Hoppe, Schmidt, and de Peyster, I963; Mikhalev, Dorokhova, and Smolina, I963) , radiation sickness (Foye and Kay, I962) , and angina pectoris (Jouve, Gras, and Benyamine, I963) .
The toxicity of piperazine has been reviewed by White and Standen (1953) who report that 'no important toxic effects have been recorded', and by Brown et al. (I956) , who reached the same conclusion.
Certain toxic effects are generally recognized, however. Martindale (I958) records that mild diarrhoea, vertigo, muscular incoordination, and paresthesiae may occur rarely and, more rarely still, nausea, vomiting, blurred vision, and urticaria. These are attributed to overdosage or accumulation of the drug.
There is only uncertain evidence that piperazine is allergenic. Hill (I957) has reported the case of a 5-year-old girl who had been given piperazine citrate without ill-effect but who, three months later, developed an acute urticaria after being given only a single further dose. Ureles (I958) has reported a case in which the administration of piperazine was followed by acute urticaria and fever and subsequently by the development of inflammatory arthritis and lymphadenopathy. Shanker and Gulati (I960) have reported a case of purpura following the administration of piperazine. The most recent such report is that of Butler (i968) .
On the other hand, Ratner and Flynn (I955) rigorously investigated the anaphylactogenic properties of piperazine citrate in the guinea-pig and concluded that 'this drug has been shown to be non-anaphylactogenic in the lower animal; it should be regarded as a nonallergenic drug'.
More recently, attention has turned to the occasional neuropathogenic effects of piperazine (Point, I965; Neff, I966; Nickey, I966; Schuch,  Stephan, and Jacobi, I966).
Only in the French literature (Foussereau, I963) has piperazine been reported to cause contact dermatitis; its action as a respiratory allergen is, so far as I am aware, unrecorded. This paper discusses these two aspects of its toxicity, which represent a hazard to those who are occupationally exposed to the substance rather than to those to whom it is therapeutically administered. It is shown that the cutaneous response to piperazine is highly dependent on environmental temperature.
The Present Study
The present study was undertaken when it appeared that workers exposed to piperazine were developing allergic reactions to it. The preparation concerned was a sheep drench in the manufacture of which piperazine hexahydrate and tartaric acid were mixed in aqueous solution, converting the piperazine to the tartrate, to which solution copper sulphate and sodium arsenite were added. Every effort was made to protect the exposed men. While handling piperazine they wore gauntlets extending almost to the armpits, a great apron covering them from above the nipple line nearly to the ankles, and a positive-pressure respirator totally enclosing the head and nearly the whole of the thorax. After finishing the job they stripped, showered, and changed to clean clothes. These measures failed to isolate them from the allergen, and, in the course of a year, four of seven exposed operatives at Kingsgrove Laboratories were sensitized.
The Results It appears from Table I that piperazine hexahydrate applied for 48 hours in an aqueous solution containing 25 g./Ioo ml. may act as a primary irritant. The most remarkable finding, however, is that piperazine-K appears to be much more irritant than piperazine-BW, the two preparations being apparently identical and both having been shown to conform to the specifications of the B.P. and the U.S.P. Application of the t test shows that the difference is significant with P between 0-02 and O0oI. However, as the number of subjects was rather small and the result so unexpected, it was advised that the result should be confirmed by a larger sample. The observation was repeated in February I966, and the results of December I964 were reproduced (Table II) . If one combines the results of December I964 and of February I966, the sample is sufficiently large and the difference between the irritant effect of the two piperazines clearly significant. The t test gives a value of P less than O0oI.
Cutaneous Allergenicity
Methods and Materials Piperazine is not a widely recognized allergen (Schwartz, Tulipan, and Birmingham, I957 ) and the concentration that should be used to test for sensitivity was not known. It was thus necessary to determine the concentration below which there would be no irritant effect. This was done concurrently with the investigation of primary irritancy in December I964.
Eight men in whom there was no clinical evidence of sensitivity wore patches moistened with aqueous solutions containing 25, 5, i, and O-I g./Ioo ml. piperazine hexahydrate. From this observation it was concluded that piperazine did not operate as a primary irritant at concentrations of 5 g./ioo ml. or less.
Four men in whom there was clinical evidence of sensitivity were also tested. Two of these had already been tested elsewhere for sensitivity to piperazine (using irritant concentrations) and had given strongly, indeed incapacitatingly, positive reactions and so the 25 and 5 g./ioo ml. solutions were not used on them. Another of the four men had had no positive patch test, but in view of the strongly suggestive clinical history the 25 g./100 ml. solution was omitted.
Results These are shown in Table III . It appears that, for patch testing, a solution of Table I. 5g./IO ml. should be used. In France, Foussereau (I963) has reached the same conclusion. Although cutaneously sensitized subjects reacted a little more strongly to piperazine-K than to piperazine-BW, the difference is not significant, nor does weighting of score for duration of exposure materially affect this position. Much more important is the fact that all four subjects suffered an exacerbation of their symptoms attributed to piperazine remote from the patch sites.
Effect of Temperature on Cutaneous Response It will be recalled that, to increase the sample size, the observation of December I964 was repeated in February I966. During the intervening months repeated attempts had been made and had failed to repeat the earlier observation (Tables IV  and V ). The effect of environmental temperature on cutaneous response is shown in Table VI . The relation between temperature and response is significant (r = O 9I, P < o.oi). followed by an abatement and then the disappearance of his symptoms. On January 6 I965, he showed no respiratory abnormality. Auscultation and fluoroscopy were normal, vital capacity was 3-7 1., one-second forced expiratory volume (F.E.V.1.0) 2-7 1. and maximum expiratory flow rate 460 1./min.; blood pressure was I40/80 mm. Hg and the heart was normal.
He returned to work on January i9; on January 2I he noticed some return of his dyspnoea and on the night of January 22 all his symptoms returned. This recurrence had occurred despite 6 the most careful avoidance of piperazine after his return to work. On January 25 auscultation was again normal but vital capacity was only 2 6 1. and the F.E.V.1.0 was 2-2 litres. He was ordered not to return to work and again his symptoms remitted. At this stage it seemed very probable that his condition was a consequence of occupational exposure but it was not clear that piperazine was to blame, especially as he had so carefully avoided all contact with it. On January 29 he was artificially exposed to piperazine-K alone. There was no change in his indices of lung function before and immediately Tables I, II, III, and IV. after exposure but that night he suffered a severe exacerbation of all his symptoms. On the following day he had prolonged expiratory sounds, scattered rhonchi, and fine crepitant rales in both bases. Prednisone was given to terminate the attack. There appears, therefore, no doubt that piperazine hexahydrate was responsible.
Discussion
Piperazine-K and Piperazine-BW A biological difference between two apparently identical preparations of piperazine hexahydrate has been shown to exist, one being much more irritant than the other in non-sensitized subjects. Both were found to conform with the requirements, of the B.P. and the U.S.P., and no chemical difference has been detected (Romer, I965 (Foussereau, I963) .
Of practical importance is the observation of the effect of environmental temperature on subject response. The cooler the workplace the more safely may piperazine be handled. Indeed, comparison of the experience at Kingsgrove Laboratories with that at the other laboratories suggests that this is a much more important precaution than are the more usual methods of protective clothing, positive, pressure respirators, change of clothing after exposure, etc. In retrospect one can observe that the mixing vat used there was in a much cooler and better ventilated place than that used at Kingsgrove Laboratories.
One manufacturer in the United States has reported that the lower the temperature the less commonly is skin sensitivity observed. This is consistent with the response of the patient J.M. In December I964, when the effective temperature was 59sF., he responded to a 5 g./Ioo ml. solution with erythema and vesiculation after 24 hours; but in June I965, when the effective temperature was 45°F., he was inadvertently exposed to a solution of 20 g./ioo ml. and showed no dermal response although he wore the patch for 48 hours. It (Pepys, I966) . Pepys has observed a similarly delayed asthmatic response to tuberculin.
It appears that piperazine is a respiratory allergen. At Kingsgrove Laboratories one of seven exposed workers was affected. In another chemical plant in Sydney piperazine, as the carbon disulphide complex, apparently quite commonly gave rise to respiratory sensitivity. In England, where the offending agent is again the carbon disulphide complex, 'exposed persons are not universally affected though the proportion is high'. In Sweden it is said, 'Those having respiratory allergy are by no means peculiar. ' Since piperazine apparently gives rise to this form of respiratory allergy fairly widely, it would be desirable that manufacturers should advise those customers who handle it of the dangers. 
